Bluejay Diagnostics, Inc. Stock

Equities

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-05-24 pm EDT 5-day change 1st Jan Change
0.49 USD -1.61% Intraday chart for Bluejay Diagnostics, Inc. -15.52% -59.84%
Sales 2022 0.25 Sales 2023 - Capitalization 1.51M
Net income 2022 -9M Net income 2023 -9M EV / Sales 2022 -7,813,548 x
Net cash position 2022 9.6M Net cash position 2023 1.84M EV / Sales 2023 -
P/E ratio 2022
-0.82 x
P/E ratio 2023
-0.13 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 84.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.61%
1 week-15.52%
1 month-10.89%
3 months-34.67%
6 months-84.19%
Current year-59.84%
More quotes
1 week
0.41
Extreme 0.4072
0.59
1 month
0.39
Extreme 0.39
0.67
Current year
0.39
Extreme 0.39
1.22
1 year
0.39
Extreme 0.39
13.98
3 years
0.39
Extreme 0.39
125.00
5 years
0.39
Extreme 0.39
125.00
10 years
0.39
Extreme 0.39
125.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 14-12-31
Founder 52 14-12-31
Chief Administrative Officer - -
Members of the board TitleAgeSince
Director/Board Member 77 21-04-30
Director/Board Member 77 16-12-31
Director/Board Member 58 21-11-14
More insiders
Date Price Change Volume
24-05-24 0.49 -1.61% 31,347
24-05-23 0.498 +0.52% 28,739
24-05-22 0.4954 -2.96% 70,195
24-05-21 0.5105 -5.55% 30,808
24-05-20 0.5405 -6.81% 17,027

Delayed Quote Nasdaq, May 24, 2024 at 04:30 pm EDT

More quotes
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
More about the company